Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597176 | 1.00 | FGFR4 (0.42) | FGFR4AURKAMAPKAPK2BTKKDM4E | |
| SCHEMBL22023327 | 0.87 | FGFR4 (0.34) | FGFR4BTK | |
| SCHEMBL18095691 | 0.85 | FGFR4 (0.34) | FGFR4BTK | |
| SCHEMBL30773936 | 0.85 | FGFR4 (0.34) | FGFR4BTK | |
| SCHEMBL29597266 | 0.82 | ALDH1A1 (0.35) | FGFR4BTKALDH1A1 | |
| SCHEMBL22023361 | 0.82 | ALDH1A1 (0.35) | FGFR4BTKALDH1A1 | |
| SCHEMBL22023306 | 0.80 | BTK (0.40) | FGFR4BTKSYK | |
| SCHEMBL18095653 | 0.75 | FGFR4 (0.78) | FGFR4 | |
| SCHEMBL30386350 | 0.70 | FGFR4 (0.79) | FGFR4 | |
| SCHEMBL19923091 | 0.67 | KDM4E (0.36) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663285-B1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-3663285-B1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20210130323-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130323-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-3663285-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885AURKA 1003/4885MAPKAPK2 998/4885 |
| US-20210130323-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885AURKA 1003/4885MAPKAPK2 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.